CALGARY,
Oct. 29, 2015 /PRNewswire/ -
Oncolytics Biotech® Inc. ("Oncolytics" or the "Company")
(TSX:ONC; NASDAQ:ONCY) announced today that it has received
notification from OTC Markets Group Inc. of its qualification for
trading in the United States on
the OTCQX® Best Market ("OTCQX").
In addition, the Company has received notice from
the Nasdaq OMX Group ("Nasdaq") stating that, in accordance with
Nasdaq listing rules, the Company's shares will be delisted from
the Nasdaq Capital Market, effective from the opening of trading on
November 5th, 2015, for
not maintaining the minimum $1.00 per
share required for continued listing under Listing Rule
5550(a)(2).
Oncolytics expects to begin trading on the OTCQX
under the symbol "ONCY" on November
5th, 2015. Investors will be able to find current
financial disclosure and Real-Time Level 2 quotes for the Company
on www.otcmarkets.com.
The Company's shares continue to trade on the
Toronto Stock Exchange ("TSX") under the symbol "ONC" and are in
full compliance with TSX listing requirements. The Company's
listing on the TSX is completely independent of, and will not be
affected by, the status of its OTCQX quotation and its Nasdaq
delisting.
About Oncolytics Biotech®
Inc.
Oncolytics is a Calgary-based biotechnology company focused on
the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics' clinical program includes a variety
of later-stage, randomized human trials in various indications
using REOLYSIN®, its proprietary formulation of the
human reovirus. For further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933,
as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian
securities laws. Statements, other than statements of historical
facts, included in this press release that address activities,
events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as the
anticipated start of trading on the OTCQX, and other such matters
are forward-looking statements and forward-looking information and
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements and forward-looking information.
Such risks and uncertainties include, among others, risks related
to market conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties
relating to the forward-looking statement and forward-looking
information. Investors are cautioned against placing undue reliance
on forward-looking statements and forward-looking information. The
Company does not undertake to update these forward-looking
statements and forward-looking information, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.